NeuBase Therapeutics Inc (NBSE)
0.378
0.00 (0.00%)
USD |
NASDAQ |
May 14, 16:00
NeuBase Therapeutics Cash from Financing (Quarterly): -0.1745M for Sept. 30, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | -0.1745M |
| June 30, 2023 | 4.546M |
| March 31, 2023 | -0.0884M |
| December 31, 2022 | -0.0286M |
| September 30, 2022 | -0.0273M |
| June 30, 2022 | -0.0276M |
| March 31, 2022 | -0.0271M |
| December 31, 2021 | -0.175M |
| September 30, 2021 | -0.1553M |
| June 30, 2021 | 42.52M |
| March 31, 2021 | 0.00 |
| December 31, 2020 | -0.0261M |
| September 30, 2020 | -0.0108M |
| June 30, 2020 | 33.24M |
| March 31, 2020 | -0.0495M |
| December 31, 2019 | -0.0734M |
| September 30, 2019 | 13.67M |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | -0.0732M |
| September 30, 2018 | -0.1083M |
| June 30, 2018 | -0.1064M |
| March 31, 2018 | 0.0098M |
| December 31, 2017 | 0.1186M |
| September 30, 2017 | -0.0086M |
| Date | Value |
|---|---|
| June 30, 2017 | 12.59M |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 6.878M |
| September 30, 2016 | -0.0432M |
| June 30, 2016 | -0.0724M |
| March 31, 2016 | 0.00 |
| December 31, 2015 | -0.0345M |
| September 30, 2015 | -0.0712M |
| June 30, 2015 | -0.07M |
| March 31, 2015 | 26.64M |
| December 31, 2014 | -0.0409M |
| September 30, 2014 | -0.065M |
| June 30, 2014 | 16.85M |
| March 31, 2014 | 0.0008M |
| December 31, 2013 | 0.186M |
| September 30, 2013 | -0.0013M |
| June 30, 2013 | 5.011M |
| March 31, 2013 | 0.0728M |
| December 31, 2012 | 0.0973M |
| September 30, 2012 | 1.707M |
| June 30, 2012 | 1.095M |
| March 31, 2012 | 0.0983M |
| December 31, 2011 | 1.05M |
| September 30, 2011 | 0.00 |
| June 30, 2011 | -0.0017M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.175M
Minimum
Dec 2021
42.52M
Maximum
Jun 2021
5.173M
Average
-0.0272M
Median
Cash from Financing (Quarterly) Benchmarks
| Ampio Pharmaceuticals Inc | 0.00 |
| Stoke Therapeutics Inc | 1.717M |
| ABVC BioPharma Inc | 0.0874M |
| MAIA Biotechnology Inc | 5.025M |
| Aprea Therapeutics Inc | 0.00 |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -2.003M |
| Free Cash Flow | -14.85M |
| Free Cash Flow Per Share (Quarterly) | -0.7262 |
| Free Cash Flow Yield | -2.02K% |